Eli Lilly (LLY) announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares of common stock of Point Biopharma (PNT) for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LLY:
- Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023
- Eli Lilly announces FDA approval of Jaypirca
- ‘Impressive’ Altimmune data likely drives strategic interest, says B. Riley
- Cantor starts Novo Nordisk with Overweight on obesity growth runway
- Eli Lilly price target raised to $680 from $600 at Berenberg